Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
481-500 of 604 trials

Multiple Myeloma: [68Ga]Ga-PentixaFor Imaging Study

We are exploring a new imaging method to see how well it detects multiple myeloma lesions in patients at diagnosis or relapse. This study may help improve the way we monitor and treat this condition.

Multiple Myeloma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

HPV-Negative Head and Neck Cancer: PARP Inhibitor and Immunotherapy Study

We are investigating a new treatment combining a PARP inhibitor and immunotherapy for patients with HPV-negative head and neck cancer. The study aims to see how well this treatment works and its safety compared to standard options.

Oropharyngeal Squamous Cell CarcinomaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Parkinson's Disease: CVN424 Study

We are testing a new medication, CVN424, for people with Parkinson's disease to see if it helps reduce OFF time and improve overall motor function. The study also aims to evaluate its safety and effects on quality of life.

Parkinson's Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Baricitinib for Children Hospitalized with COVID-19

We are studying how the medication baricitinib works in children aged 1 to under 18 years who are hospitalized with COVID-19. This research aims to ensure the safety and proper dosing for young patients.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Tardive Dyskinesia: Testing ADE513

We are studying a new medication to see if it helps reduce involuntary movements in people with moderate to severe tardive dyskinesia. The trial also looks at the safety and tolerability of this treatment.

Tardive Dyskinesia3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyPsychiatry

Rheumatoid Arthritis: Spironolactone Study

We are investigating whether spironolactone can help reduce symptoms in people with active rheumatoid arthritis. The study will also monitor safety and other health indicators.

Rheumatoid Arthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Diffuse Large B-Cell Lymphoma: Polatuzumab Vedotin with R-CHP

We are studying whether a new treatment combining polatuzumab vedotin with standard chemotherapy helps patients with diffuse large B-cell lymphoma live longer without disease progression compared to the current standard treatment.

Diffuse Large B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Lymphoma Treatment: Loncastuximab Tesirine

We are studying a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma after CAR T-cell therapy. The goal is to see if it improves response rates and survival outcomes.

B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Bladder Cancer: Intravesical Gemcitabine Treatment

We are studying the effectiveness and safety of a drug called gemcitabine for patients with low-grade bladder cancer. This trial aims to see how well it works in treating this specific type of cancer.

Bladder Cancer≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Bipolar Depression: Lithium vs. Cariprazine

We are comparing the effectiveness of lithium and cariprazine for treating acute depressive episodes in people with bipolar disorder. The goal is to find out which medication may lead to better improvements in mood.

Depressive Episode in Bipolar Disorder≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Schizophrenia Treatment: Cannabidiol vs. Placebo

We are studying whether adding cannabidiol to standard antipsychotic treatment helps improve recovery in early schizophrenia. The trial will also look at safety and changes in mental and social functioning.

Remitted Schizophrenia1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

Advanced Lung Cancer: Atezolizumab vs. Atezolizumab Plus Bevacizumab

We are studying whether adding bevacizumab to atezolizumab helps patients with advanced non-small-cell lung cancer live longer than using atezolizumab alone. This trial is for those with high PD-L1 expression who have not yet received treatment.

Advanced Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Heart Attack Recovery: Ferric Carboxymaltose Treatment

We are studying whether intravenous ferric carboxymaltose can improve survival and quality of life in iron-deficient patients who recently had a heart attack. This trial compares its effects to a placebo treatment.

Recent Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCardiologyInternal Medicine

TOASST Study: Comparing Steroid Withdrawal Methods

We are studying whether stopping glucocorticoids suddenly is as safe as tapering them for patients with inflammatory disorders. This research may help improve treatment strategies and patient outcomes.

Inflammatory or Autoimmune Disorders>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Statin Therapy for Frail Older Adults After Stroke

We are studying whether starting statin medication helps frail individuals aged 70 and older who have had a recent stroke or transient ischemic attack. The goal is to see if it improves heart health and quality of life.

Ischemic Stroke and Transient Ischemic Attack>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Metformin for Small Abdominal Aortic Aneurysms

We are studying if taking metformin daily can slow the growth of small abdominal aortic aneurysms in patients without diabetes. This trial also looks at the safety and quality of life for participants.

Small Abdominal Aortic Aneurysm>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pancreas and Kidney Transplant: Sirolimus vs. Mycophenolate Mofetil

We are comparing two medications to see which one may reduce the risk of hernias after simultaneous pancreas and kidney transplants in people with type 1 diabetes. We also want to understand their effects on diabetes complications.

End-stage Kidney Disease in Type 1 DiabetesTransplantation ComplicationsSimultaneous Pancreas and Kidney Transplantation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal MedicineNephrologyOncologyUrology

Dental Implants: Antibiotic Use in Bone Augmentation

We are studying whether short or long-term antibiotic use is more effective during dental implant surgery. This trial will also look at how these antibiotics affect bacteria in the mouth and gut.

Need for Oral Bone Augmentation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology